Orchestra BioMed (OBIO) announced the first patient enrollments in the Virtue SAB in the Treatment of Coronary ISR Trial, the Company’s U.S. IDE pivotal trial comparing its highly differentiated Virtue Sirolimus AngioInfusion Balloon to the AGENT paclitaxel-coated balloon, currently the only drug-coated balloon FDA-approved for a coronary indication. Designed to support regulatory approval of Virtue SAB, the Virtue Trial is expected to enroll 740 patients at up to 75 centers in the United States with enrollment completion currently planned for mid-2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO: